{"schema_version":"secwatch.filing_event.v1","accession":"0001826466-23-000033","form_type":"8-K","ticker":"NIKA","cik":"0001145604","company_name":"NIKA PHARMACEUTICALS, INC","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.243882+00:00","generated_at":"2026-06-10T14:28:26.420887+00:00","sec_items":["1.01","2.01","9.01","3.02","3.03","5.01","5.06"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nika Pharmaceuticals provides Form 10 info, discloses ownership and auditor change as former shell","bullets":["Change of control completed Apr 1, 2022: Dimitar Savov acquired 87% of common stock for $140,000.","As of Aug 31, 2023, Savov holds 38.04% common stock and 100% preferred stock, controlling 100% voting power.","Company ceased to be a shell as of Apr 11, 2022; business focus on TNG production and dietary supplements.","Auditor changed: dismissed Pinnacle Accountancy Group on Aug 18, 2022; engaged BF Borgers CPA PC on Oct 24, 2022.","Common stock not traded on any exchange; approximately 64 holders of record as of Sept 14, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001826466-23-000033","json":"https://secwatch.observer/filing/0001826466-23-000033.json","markdown":"https://secwatch.observer/filing/0001826466-23-000033.md","text":"https://secwatch.observer/filing/0001826466-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1145604/000182646623000033/0001826466-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1145604/000182646623000033/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:28:26.420887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"337b0f809e6d913c7fb1dc319706b22ee922497c","claim":"NIKA PHARMACEUTICALS, INC underwent a change of control involving Dimitar Slavchev Savov for $140,000 (closed 2022-04-01).","evidence_excerpt":"As a result of the purchase by Dimitar Slavchev Savov of a total of 11,489,000 (87%) shares of common stock of the Company from the Company’s former President and CEO, Mr. Phil E. Ray and certain other shareholders for $140,000, a change in control of the Company occurred as of April 1, 2022.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1145604/000182646623000033/0001826466-23-000033-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Dimitar Slavchev Savov"},{"label":"Consideration","value":"$140,000"},{"label":"Closing","value":"2022-04-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}